Introduction
High-dose chemotherapy followed by auto-SCT improves the long-term outcome of some patients with nonHodgkin's lymphoma and Hodgkin's lymphoma. [1] [2] [3] Whether chemotherapy should be used in addition to growth factors for stem cell mobilization is controversial. Etoposide is an effective mobilizing agent, 4 but one report identified it as a significant risk factor for the development of therapy-related myelodysplasia (tMDS) and therapyrelated AML (tAML). 5 We compared the safety and effectiveness of high-dose etoposide followed by G-CSF (VP þ G) to G-CSF alone for PBPC mobilization in a large cohort of patients with prolonged follow-up.
Patients and methods

Patient characteristics
A total of 958 patients who underwent auto-SCT (ASCT) at the Cleveland Clinic or Ohio State University (OSU) between February 1992 and June 2006 were included. Patient characteristics are summarized in Table 1 . Data regarding treatment received before ASCT were obtained from medical records provided to us by referring physicians at the time of initial patient evaluation or retrospectively. After auto-SCT, patient outcome data were captured prospectively and accessed through the Cleveland Clinic Transplant Center and OSU Transplant Database. All patients were treated on clinical trials approved by each center's Institutional Review Board, and all patients provided written informed consent.
PBPC mobilizing regimen
A total of 640 patients received etoposide 2 g/m 2 based on adjusted ideal body weight ((actual body weightÀideal body weight)/4 þ ideal body weight) with G-CSF (10 mg/kg per day s.c.) and 318 patients received G-CSF 10 mg/kg per day s.c. alone. This was done in the outpatient setting in a non-randomized manner depending on the year of trans-plant. Patients who failed to yield with G-CSF alone and subsequently yielded with VP þ G were analyzed in the VP þ G-CSF arm. Leucapheresis was initiated once WBC recovered to greater than 5 Â 10 9 per L in patients receiving etoposide and on the fifth day of G-CSF administration in those receiving G-CSF alone. In general, patients who yielded X2 Â 10 6 CD34 þ cells per kg were eligible for transplantation. Of those who underwent transplantation, 21 patients yielded o2 Â 10 6 CD34 þ cells per kg.
Preparative regimen and autologous transplantation
The preparative regimen used was busulfan 14 mg/kg, etoposide 60 mg/kg and cyclophosphamide 120 mg/kg. Patients were hospitalized for the administration of the preparative regimen and routinely discharged after hematological recovery.
Statistical analysis
Categorical variables are compared between the two groups using the w 2 -test. Continuous variables are compared using the Wilcoxon rank sum test.
OS and relapse-free survival were estimated using the Kaplan-Meier method and compared between the two groups using the log-rank test. Relapse and tMDS/tAML were estimated using the cumulative incidence method and compared between the two groups using the Pepe-Mori test. Stepwise Cox proportional hazards analysis with a variable entry criterion of Pp0.10 and a variable retention criterion of Pp0.05 was used to identify multivariable prognostic factors for each outcome. Results are presented as the hazard ratio (HR), 95% confidence interval (CI) for the HR and corresponding P-value. All statistical tests were two-sided, and Pp0.05 was used to indicate statistical significance. Analyses were performed using SAS software (SAS Institute Inc., Cary, NC, USA).
Results
The clinical characteristics of the 318 patients who received G-CSF alone are compared with that of the 640 patients who received VP þ G in Table 1 . Patients who received VP þ G were older (Po0.001), received more courses of chemotherapy before transplantation (P ¼ 0.036) and more frequently had relapsed/refractory disease (Po0.001). In the group receiving VP þ G, 331 patients (52%) are alive with a median follow-up of 57.6 months (range, 3.3-166.9 months). In the G-CSF group, 153 (48%) patients are alive with a median follow-up of 114.2 months (range, 15.3-181.9 months).
In the VP þ G group, the median total CD34 þ cells collected was 9.34 Â 10 6 per kg (range 0.97-180.89), with 42% of all patients having adequate (2 Â 10 6 cells per kg) CD34 þ collection after 2 days of apheresis compared with a median CD34 þ cells of 3.83 Â 10 6 per kg collected in the G-CSF group (range, 0.72-50.38), with 16% patients having adequate collection after 2 days (Po0.001).
Post-priming readmissions for neutropenic fever were required in 139 patients (27%) in the VP þ G group, none of which were fatal, and none in the G-CSF alone group. Following transplantation, median time to neutrophil engraftment was 10 days in both the G-CSF alone group (range 8-30) and in the VP þ G group (range 5-17). Time to platelet recovery in the G-CSF alone group was 13 days (range, 7-427) and in the VP þ G group was 15 days (range, 6-97; Po0.001; Table 2 ). The incidence of death within 100 Table 2 Comparison between priming regimens Etoposide plus G-CSF priming in lymphoma A Mahindra et al days of transplantation was 5% in the G-CSF alone group and 4.5% in the VP þ G group (P ¼ 0.73). Following transplantation, tMDS/tAML occurred in 15 patients (2%) in the VP þ G group and in 12 (4%) patients receiving G-CSF alone (P ¼ 0.62; Pepe-Mori test; Table 3 ). The estimated incidence of tMDS/tAML at 5 years was 2% in the VP þ G group and 2.6% in the G-CSF alone group as shown in Figure 1 . Since many of the patients were referred from outside institutions and subsequent care post transplantation was with the referring physician as well, details regarding therapy post transplantation are not reliably available and hence not included here.
There was no significant difference in the incidence of relapse (P ¼ 0.19) or relapse-free survival (P ¼ 0.34) between the two groups ( Figure 2) . OS was inferior in the VP þ G group (P ¼ 0.044) in univariate analysis (Figure 3) . Adjusting for transplant center, multivariable analysis Univariate analysis demonstrated that a higher number of previous chemotherapy regimens and an increased number of days of pheresis were prognostic factors for the development of tMDS/tAML (Table 4) . On multivariable analysis, increased number of days of apheresis alone was prognostic for tMDS/tAML (HR 1.19, 95% CI 1.08-1.30, Po0.001).
Discussion
The present study shows that even when restricted to patients who yield adequate numbers of PBPCs for transplantation, the addition of etoposide significantly improves the effectiveness of mobilization. This occurs at the cost of the expense and toxicity of additional chemotherapy and an increased incidence of neutropenic fever, although with no mortalities. Furthermore, we have previously shown that etoposide is effective in reducing the burden of tumor in patients with lymphomas. 4 Following auto-SCT, tMDS/tAML has been reported to occur in up to 15% of patients. [6] [7] [8] [9] [10] One previous study 5 implicated priming with VP-16 as a significant factor for development of tAML following ASCT. A subsequent report detected no increased risk for tMDS/tAML with VP-16 mobilization in the absence of TBI conditioning.
11
tMDS/tAML following VP-16 occurs with a much shorter latency period than following alkylating agents and other treatments. 12 Our study analyzed the largest cohort of patients mobilized with VP-16 and G-CSF with a median follow-up much longer than the median time to VP-16-related tMDS/tAML.
Priming regimen was not a significant variable for relapse-free or OS on multivariable analysis. The inferior OS on univariate analysis in patients receiving VP þ G appears to be related to greater number of older patients, the higher incidence of relapsed/refractory disease at the time of transplant and their having received more previous chemotherapy regimens, all of which are adverse prognostic factors for survival. The adverse prognostic impact of increased days of apheresis on tMDS/tAML likely reflects the presence of an impaired stem cell compartment in these patients, which leads to difficult mobilization and increased secondary malignancies on long-term follow-up. 13 As this is a retrospective study with a long follow-up, details regarding treatment received before or subsequent to transplant are not available and included in the multivariate analysis may have influenced our results regarding significance of days of pheresis.
The impact of efficient PBPC mobilization and collection may extend beyond achieving adequate numbers for infusion. Poor mobilization is a risk factor for worse outcome.
14 Patients mobilizing larger numbers of CD34 þ cells have improved survival following autologous transplantation for lymphoma. 15, 16 VP-16 with G-CSF is an effective and useful method of mobilization in patients with lymphomas. Our data do not demonstrate an increased incidence of tMDS/tAML compared with patients mobilized with G-CSF alone. Recently developed regimens, like plerixafor plus G-CSF, may be as or more effective than VP-16 and potentially with less toxicity, but are more expensive and require further long-term studies. Etoposide plus G-CSF priming in lymphoma A Mahindra et al
